Daiichi Sankyo Begins First-in-Human Trial of STING Agonist ADC DS3610 for Advanced Solid Tumors
Daiichi Sankyo Co. Ltd. has initiated a first-in-human phase 1 clinical trial for DS3610, a STING agonist antibody drug conjugate targeting advanced solid tumors. This investigational drug aims to utilize the body's immune system to combat cancer. The trial represents the first clinical evaluation of DS3610, with no specific research results available yet. The announcement coincides with the dosing of the first patient.
Daiichi Sankyo Co. Ltd. has announced the initiation of a first-in-human phase 1 clinical trial for DS3610, an investigational STING agonist antibody drug conjugate (ADC), in patients with advanced, metastatic, or unresectable solid tumors. DS3610, which features an immunomodulatory payload, represents a novel approach aiming to harness the body’s own immune defenses to target cancer. This trial marks the first clinical evaluation of DS3610, and no specific research results have been presented yet; the development was announced as the first patient was dosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110993494) on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
